


Daclatasvir + Sofosbuvir (Daklinza® + Sovaldi®) for Genotype 3

Preliminary data suggest that NS5A Genotype 3 RAV testing is recommended for all genotype 3 patients prior to treatment. Consult Liver Disease Specialist first*.



*Consult Liver Disease Specialist before prescribing treatment for persons with genotype 3, past treatment failure, cirrhosis, hepatocellular carcinoma (HCC), renal disease, pre- and post-liver transplant, or HIV or hepatitis B co-infection.

**Use low initial dose ribavirin: 600mg increased to weight-based ribavirin dose as tolerated.

***Daklinza + Sofosbuvir- Consider for persons who cannot take ribavirin.

Link to AASLD/IDSA Guidelines: <http://hcvguidelines.org/full-report-view>

¹Peg/RBV = Pegylated interferon/ Ribavirin

²Sof/RBV = Sofosbuvir/Ribavirin